Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Current Deferred Revenue: 2021-2023

Historic Current Deferred Revenue for InMed Pharmaceuticals (INM) over the last 2 years, with Dec 2023 value amounting to $28,656.

  • InMed Pharmaceuticals' Current Deferred Revenue rose 77.21% to $28,656 in Q4 2023 from the same period last year, while for Dec 2023 it was $28,656, marking a year-over-year increase of 77.21%. This contributed to the annual value of $16,171 for FY2023, which is N/A change from last year.
  • InMed Pharmaceuticals' Current Deferred Revenue amounted to $28,656 in Q4 2023, which was up 77.21% from $16,171 recorded in Q2 2023.
  • InMed Pharmaceuticals' 5-year Current Deferred Revenue high stood at $28,656 for Q4 2023, and its period low was $8,390 during Q4 2021.
  • Its 3-year average for Current Deferred Revenue is $15,737, with a median of $16,171 in 2023.
  • Data for InMed Pharmaceuticals' Current Deferred Revenue shows a peak YoY surged of 92.74% (in 2022) over the last 5 years.
  • InMed Pharmaceuticals' Current Deferred Revenue (Quarterly) stood at $8,390 in 2021, then skyrocketed by 92.74% to $16,171 in 2022, then skyrocketed by 77.21% to $28,656 in 2023.
  • Its Current Deferred Revenue stands at $28,656 for Q4 2023, versus $16,171 for Q2 2023 and $16,171 for Q1 2023.